Evidence map›Paper›PMID 41425712›Full record

ArticleOncology research2025

Exosomal miR-17 Drives Thyroid Cancer Lung Metastasis via NF-

Yan Gui, Wen Pan, Ziyi Dong, Dongzhi Hu, Yaoyang Guo, Xinyi Wen, Haiyang Zhang, Zhansheng Jiang, Xiangqian Zheng, Ming Gao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yan GuiThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Wen PanThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Ziyi DongThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Dongzhi HuThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Yaoyang GuoThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Xinyi WenThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Haiyang ZhangTianjin Institute of Coloproctology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China.
Zhansheng JiangThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Xiangqian ZhengThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.
Ming GaoTianjin Institute of Coloproctology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin, 300121, China.
Junyi WangThe First Hospital of Lanzhou University, The First School of Clinical Medicine, Lanzhou University, Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, Lanzhou, 730030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Metastatic spread to the lung is one of the leading causes of fatal outcomes in thyroid cancer, but the underlying molecular mechanisms remain unclear. To investigate how exosomal microRNA-17-5p (miR-17-5p) promotes lung metastasis in thyroid cancer within the framework of the "seed and soil" hypothesis. Methods: Serum exosomes from thyroid cancer lung metastasis patients and controls were analyzed for miR-17, which was elevated in metastatic cases. miR-17 was transfected into embryonic lung fibroblasts (MRC-5), and their supernatants were co-cultured with thyroid cancer cells (Cal62). Cell proliferation and migration were evaluated using colony formation, Ki67 staining, and Transwell assays. Interleukin-6 (IL-6)/interleukin-8 (IL-8) levels and nuclear factor kappa-B (NF-κB)/nuclear factor kappa-B repressing factor (NKRF) expression were analysed by enzyme-linked immunosorbent assays (ELISA) and western blot. Results: miR-17-5p was significantly enriched in serum exosomes of metastatic patients. In MRC-5 cells, it suppressed NKRF, NF-κB signaling, and increased secretion of IL-6 and IL-8, enhancing Cal62 proliferation and migration. Animal experiments confirmed its role in promoting tumor growth and lung metastasis. Conclusions: Exosomal miR-17-5p remodels the pulmonary microenvironment into a pro-inflammatory niche, facilitating thyroid cancer colonization and offering a potential therapeutic target.

Indexed as

ExosomesLung NeoplasmsMicroRNAsNF-kappa BThyroid NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansInterleukin-8MaleMiceMiddle AgedInterleukin-8MicroRNAsMIRN17 microRNA, humanNF-kappa Bexosomesinflammatory environmentmicroRNA-17Thyroid cancertumor metastasis

Identifiers

PMID41425712
PMCPMC12712653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.